Press Releases

Aug 15, 2022 AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

Aug 15, 2022 AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 28, 2022 AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jul 20, 2022 AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Jul 18, 2022 AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid

Jul 14, 2022 AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series

Jun 21, 2022 AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing

Jun 13, 2022 AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

May 19, 2022 AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022 AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program

1 2 3 4 5 6 7 8

<< < > >>